Articles published by BeiGene
![](https://mms.businesswire.com/media/20240807337131/en/2209298/5/Q2Static_2024_V3_%281%29_%281%29.jpg)
![](https://mms.businesswire.com/media/20240313093081/en/2064845/5/MAX_LogoFullColorRGB.jpg)
![](https://mms.businesswire.com/media/20231013755802/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
October 13, 2023
From BeiGene
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20230831049013/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
![](https://mms.businesswire.com/media/20230721581393/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
July 21, 2023
From BeiGene
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20230712289601/en/1839275/5/MehrdadMobasher_HS_%281%29.jpg)
![](https://mms.businesswire.com/media/20230710061783/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
![](https://mms.businesswire.com/media/20230707825257/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023
July 07, 2023
From BeiGene
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20230615020330/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
![](https://mms.businesswire.com/media/20230609005039/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
![](https://mms.businesswire.com/media/20230525005611/en/1803602/22/Lai_Wang.jpg)
BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio
May 25, 2023
From BeiGene
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20230524005324/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
BeiGene to Present at Upcoming Investor Conferences
May 24, 2023
From BeiGene
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20230516005958/en/1795637/5/MAX_LogoFullColorRGB.jpg)
![](https://mms.businesswire.com/media/20230506005006/en/1775305/22/BeiGene_sunny.jpg)
![](https://mms.businesswire.com/media/20230425006180/en/1775322/22/BeiGene_sunny.jpg)
![](https://mms.businesswire.com/media/20230424005816/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG Report
April 25, 2023
From BeiGene
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20230420005320/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
![](https://mms.businesswire.com/media/20230417005338/en/1764924/22/MapKure_logo.jpg)
![](https://mms.businesswire.com/media/20230413005329/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
![](https://mms.businesswire.com/media/20230330005198/en/1751464/22/Julius_Pryor.jpg)
BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity
March 30, 2023
From BeiGene
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20230321005124/en/1742432/5/BeiGene_Hopewell.jpg)
![](https://mms.businesswire.com/media/20230224005112/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
February 24, 2023
From BeiGene
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20230224005039/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference
February 24, 2023
From BeiGene
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20230203005094/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care
February 03, 2023
From BeiGene
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20230201005204/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
BeiGene to Present at Upcoming Investor Conferences
February 01, 2023
From BeiGene
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20230119005888/en/1691219/22/Brukinsa_carton_bottle_capsules.jpg)
BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
January 19, 2023
From BeiGene
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20230119005082/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
![](https://mms.businesswire.com/media/20230118005571/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List
January 18, 2023
From BeiGene
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20230117006065/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium
January 17, 2023
From BeiGene
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20230104005542/en/1612468/5/BGNE-LOGO-HORTZ-COLOR-BREDMID-RGB.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.